IGHV2 5 | ENSG00000211937 | NCBI 28457

Details for: IGHV2 5

Gene ID: 28457

Gene Type: Other - A known gene or region type that lacks a specific category. Includes immunoglobulin (Ig), T-cell receptor (TCR) gene segments, and repetitive elements.

Symbol: IGHV2 5

Ensembl ID: ENSG00000211937

Description: immunoglobulin heavy variable 2-5

Cell Significance Landscape

Display Count:

Associated with

Adaptive immune system
(R-HSA-1280218)
Anti-inflammatory response favouring leishmania parasite infection
(R-HSA-9662851)
Antigen activates b cell receptor (bcr) leading to generation of second messengers
(R-HSA-983695)
Binding and uptake of ligands by scavenger receptors
(R-HSA-2173782)
Cd22 mediated bcr regulation
(R-HSA-5690714)
Cell surface interactions at the vascular wall
(R-HSA-202733)
Classical antibody-mediated complement activation
(R-HSA-173623)
Complement cascade
(R-HSA-166658)
Creation of c4 and c2 activators
(R-HSA-166786)
Disease
(R-HSA-1643685)
Fc epsilon receptor (fceri) signaling
(R-HSA-2454202)
Fceri mediated ca+2 mobilization
(R-HSA-2871809)
Fceri mediated mapk activation
(R-HSA-2871796)
Fceri mediated nf-kb activation
(R-HSA-2871837)
Fcgamma receptor (fcgr) dependent phagocytosis
(R-HSA-2029480)
Fcgr3a-mediated il10 synthesis
(R-HSA-9664323)
Fcgr3a-mediated phagocytosis
(R-HSA-9664422)
Fcgr activation
(R-HSA-2029481)
Hemostasis
(R-HSA-109582)
Immune system
(R-HSA-168256)
Immunoregulatory interactions between a lymphoid and a non-lymphoid cell
(R-HSA-198933)
Infectious disease
(R-HSA-5663205)
Initial triggering of complement
(R-HSA-166663)
Innate immune system
(R-HSA-168249)
Leishmania infection
(R-HSA-9658195)
Leishmania parasite growth and survival
(R-HSA-9664433)
Leishmania phagocytosis
(R-HSA-9664417)
Parasite infection
(R-HSA-9664407)
Parasitic infection pathways
(R-HSA-9824443)
Potential therapeutics for sars
(R-HSA-9679191)
Regulation of actin dynamics for phagocytic cup formation
(R-HSA-2029482)
Regulation of complement cascade
(R-HSA-977606)
Role of lat2/ntal/lab on calcium mobilization
(R-HSA-2730905)
Role of phospholipids in phagocytosis
(R-HSA-2029485)
Sars-cov infections
(R-HSA-9679506)
Scavenging of heme from plasma
(R-HSA-2168880)
Signaling by the b cell receptor (bcr)
(R-HSA-983705)
Vesicle-mediated transport
(R-HSA-5653656)
Viral infection pathways
(R-HSA-9824446)
Antigen binding
(GO:0003823)
Extracellular region
(GO:0005576)
Immune response
(GO:0006955)
Immunoglobulin complex
(GO:0019814)
Immunoglobulin mediated immune response
(GO:0016064)
Plasma membrane
(GO:0005886)

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

IgA plasma cell CL0000987

CSI 4.6

rCSI 4.71%

PRS 98.53
plasmablast CL0000980

CSI 3.69

rCSI 2.9%

PRS 99.21

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Context Genes (max 20):

Interaction Source:

Pathway Categories (for ONTOLOGY source):

Baseline Cell Type:

Baseline Cell Context(s): Comma-separated if multiple.

Target Cell Type:

Target Cell Context(s): Comma-separated if multiple.

Legend:

Query Gene
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
Node Size: Proportional to Target Cell CSI magnitude
STRING PPI Edge
Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

Description

## Summary [IGHV2 5](/details-gene/28457), or Immunoglobulin Heavy Variable 2-5, is a V (variable) gene segment located on chromosome 14. It encodes a crucial component of the variable region of immunoglobulin heavy chains. As a fundamental building block of antibodies, its primary function is in [antigen binding](/details-cell/GO:0003823) and the subsequent orchestration of the adaptive immune response. **Overall**, expression data indicates that [IGHV2 5](/details-gene/28457) is a key gene in terminally differentiated B-lymphocytes, showing the highest significance in antibody-secreting cells such as [IgA plasma cells](/details-cell/CL0000987) and [plasmablasts](/details-cell/CL0000980). ## Cellular Roles and Expression Landscape The expression profile of [IGHV2 5](/details-gene/28457) firmly establishes its role within the humoral immune system. The gene's significance is highest in cells responsible for antibody production, highlighting its importance in the effector phase of the B-cell lineage. - **Antibody-Secreting Cells:** The highest significance score for [IGHV2 5](/details-gene/28457) is observed in [IgA plasma cells](/details-cell/CL0000987) (CSI: 4.60) and their precursors, [plasmablasts](/details-cell/CL0000980) (CSI: 3.69). This suggests that this particular V-segment is frequently utilized in the generation of the antibody repertoire, particularly in mucosal immunity where IgA is the predominant isotype. The available data centers on the B-cell lineage, indicating that the primary role of [IGHV2 5](/details-gene/28457) is highly specialized to the production of immunoglobulins. ## Pathways and Molecular Function Functional annotation reinforces the role of [IGHV2 5](/details-gene/28457) as a cornerstone of the [adaptive immune system](/details-cell/R-HSA-1280218). Its molecular function is centered on [antigen binding](/details-cell/GO:0003823), which is the initial step in a cascade of immune processes. The gene is integral to the formation of the B-cell receptor (BCR) and secreted antibodies, placing it at the heart of pathways such as [signaling by the B cell receptor (BCR)](/details-cell/R-HSA-983705) and the [immunoglobulin mediated immune response](/details-cell/GO:0016064). Upon antigen recognition, antibodies containing the [IGHV2 5](/details-gene/28457) segment can trigger downstream effector functions, including [classical antibody-mediated complement activation](/details-cell/R-HSA-173623) and [Fcgamma receptor (FCGR) dependent phagocytosis](/details-cell/R-HSA-2029480). Furthermore, its involvement is noted in specific pathological contexts, such as responses to [infectious diseases](/details-cell/R-HSA-5663205), including [Leishmania infection](/details-cell/R-HSA-9658195) and [SARS-CoV infections](/details-cell/R-HSA-9679506). This highlights the importance of the specific antibody repertoire, shaped by V-genes like [IGHV2 5](/details-gene/28457), in host defense against diverse pathogens. ## Research Directions The specific role of [IGHV2 5](/details-gene/28457) usage in health and disease provides several avenues for future investigation. Its fundamental contribution to the antibody repertoire suggests its utilization patterns may be altered in pathological states involving the humoral immune system. **Testable Hypotheses:** 1. **Role in Autoimmunity:** The prevalence of [IGHV2 5](/details-gene/28457) usage in the B-cell repertoire may be significantly skewed in patients with certain autoimmune diseases (e.g., Systemic Lupus Erythematosus or Rheumatoid Arthritis), contributing to the production of pathogenic autoantibodies. 2. **Pathogen-Specific Responses:** Given its annotation in specific infectious disease pathways, it is hypothesized that the [IGHV2 5](/details-gene/28457) gene segment is preferentially selected in B-cell clones that generate high-affinity neutralizing antibodies against specific viral or parasitic antigens. **Proposed Experiment:** To test the hypothesis regarding autoimmunity (Hypothesis 1), a powerful approach would be to perform deep B-cell receptor sequencing (BCR-seq) on sorted [plasmablasts](/details-cell/CL0000980) and [plasma cells](/details-cell/CL0000987) from the peripheral blood of a cohort of patients with an active autoimmune disease and a matched cohort of healthy controls. This experiment would precisely quantify the frequency of [IGHV2 5](/details-gene/28457) gene segment usage within the antibody-secreting cell population, allowing for a direct statistical comparison to determine if its representation is significantly enriched in the disease state. **Therapeutic Potential:** [IGHV2 5](/details-gene/28457) itself is not a direct therapeutic target, as it is a germline gene segment. However, the specific antibodies and B-cell clones that utilize it could be highly relevant targets. If a pathogenic antibody in an autoimmune disease or a malignant clone in a B-cell cancer (e.g., multiple myeloma) is found to consistently use the [IGHV2 5](/details-gene/28457) segment, this could inform the development of therapies. Such strategies might include anti-idiotype antibodies or CAR-T cells designed to recognize and eliminate the specific B-cell clones expressing these pathogenic surface receptors. In this context, the therapeutic strategy would be one of targeted **inhibition** or depletion of specific cellular populations.

Disclaimer: This in-silico analysis is generated by an AI language model and may contain inaccuracies or hallucinations. However, it is cross-referenced with curated gene expression data from major biological sources. Please verify the information before use.